Navigation Links
Proteins stop blood-vessel and tumor growth in mice

Researchers at National Jewish Medical and Research Center report in the March issue of Cancer Research that a pair of promising proteins, known as fibulins 3 and 5, slow the growth of cancer tumors in mice by preventing blood vessels from sprouting. The proteins are promising candidates for use in cancer therapy.

"Healthy humans produce fibulin proteins, which regulate cell proliferation, migration and invasion. In the past, we have seen that they are depleted in numerous metastatic cancers, and that they inhibit the formation of new blood vessels in cell culture," said William Schiemann, Ph.D., Assistant Professor in the Program in Cell Biology at National Jewish. "Our current findings show that fibulins can inhibit both tumor growth and blood-vessel formation in mice."

Tumors need nutrients and oxygen supplied by blood vessels in order to grow. They also use blood vessels to spread to other parts of the body. This process, known as metastasis, is the most lethal stage of cancer and the leading cause of cancer-related death. Fighting cancer by starving tumors of life-giving blood vessels has generated great interest in recent years.

In their most recent experiments, Dr. Schiemann and his colleagues injected a biological material, called Matrigel, into mice. The Matrigel contained a growth factor that promotes blood-vessel growth and either a control substance or fibulin 3 or fibulin 5. After seven days, researchers found that the Matrigel plugs containing either fibulin had about half as many blood vessels as did the control plugs.

The researchers then injected fibrosarcoma tumor cells into mice. The tumor cells were genetically engineered to produce either fibulin 3 or fibulin 5. Three weeks after the cells were implanted, developing tumors that produced the fibulins were approximately 24 percent to 45 percent smaller than the control tumors.

"We are thrilled that the fibulins continue to show promise as we move into animal models," said Dr. Schiemann. "We also found evidence that the fibulins work through more than one biological pathway, which suggests a very robust effect. We further expect the mice to tolerate quite large doses of the fibulins, which makes us hopeful that toxicity will not be a problem."

The researchers have not yet discovered what receptors the fibulins interact with to produce their anti-angiogenic effect. But in the current paper, they report that the fibulins alter levels of extracellular proteins involved in dissolving and remodeling the extracellular matrix, which can make way for blood-vessel growth.

Moving forward, Dr. Schiemann is working to isolate the portion of the fibulin molecules that actually binds to receptors and causes their biological effect. If they can find a small molecule capable of producing the fibulins' effects, it would hold more promise as a viable therapy.


Source:National Jewish Medical and Research Center

Related biology news :

1. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
2. Hirsute Or Hairless? Two Proteins May Spell The Difference
3. Proteins spur diabetic mice models to grow blood vessels, nerves
4. Parallel evolution: Proteins do it, too
5. Proteins as parents
6. Proteins anchor memories in our brain
7. Proteins may behave differently in natural environments
8. Proteins necessary for brain development found to be critical for long-term memory
9. Proteins may predict lung transplant rejection
10. Proteins important in Alzheimers, Parkinsons disease travel in the slow lane
11. Mouse brain tumors mimic those in human genetic disorder
Post Your Comments:

(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply ... a time. So which eye do you rinse first if a dangerous substance enters both ... Duo Eye Wash with its unique dual eye piece. , “Whether its dirt and ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
Breaking Biology Technology: